Please ensure Javascript is enabled for purposes of website accessibility

Could Tonix Pharmaceuticals Be a Millionaire-Maker Stock?

By Cory Renauer - May 4, 2021 at 7:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech's ambitious development pipeline keeps attracting attention.

If you're not a millionaire now but would like to become one, there's a well-worn path to get there. Just buy pieces of small businesses that become much larger. 

Aspiring millionaires have been drawn to Tonix Pharmaceuticals (TNXP 12.26%), a small clinical-stage biotech with some potential new drugs in development that could be worth billions.

Can this company's potential new treatments for fibromyalgia and COVID-19 make millionaires out of bold new investors? To answer this burning question, let's start with this clinical-stage company's lead candidate.

Pharmaceutical sales meeting.

Image source: Getty Images.

Lots of good news

Tonix Pharmaceuticals doesn't have any revenue-generating assets yet, but that could change if its lead candidate, TNX-102, can earn approval to treat fibromyalgia. This chronic nerve-pain condition affects millions of American adults, and a new and improved treatment could generate billions in annual revenues.

In a phase 3 trial, fibromyalgia patients given TNX-102 achieved significant pain reductions compared to those given a placebo. Sleep disturbance is a serious issue for fibromyalgia patients, so investigators measured for this outcome as well. On the sleep quality front, TNX-102 knocked it out of the park.

Tonix also turned a lot of heads this March with positive data from its COVID-19 vaccine program. The company's lead vaccine candidate, TNX-1800, knocked it out of the park on a pre-clinical challenge study. All four subjects given TNX-1800 were protected from infection, while all four subjects given the placebo tested positive for COVID-19.

Let's get serious

As far as companies like Tonix Pharmaceuticals are concerned, Operation Warp Speed is over and done. This company will not be receiving bucketloads of cash from the U.S. government to develop TNX-1800 or any new COVID-19 vaccine.

The Tonix Pharmaceuticals lost $50 million last year, and there's no telling when the bleeding is going to stop because we still don't know if TNX-1800 has a shot at earning FDA approval. The company still hasn't injected its vaccine candidate into humans. 

Moreover, TNX-1800 uses a drug delivery method that will invite extra scrutiny from the FDA. Tonix Pharmaceuticals is using the hollowed-out husk of another virus, horsepox, to deliver genetic blueprints that should coax human cells into producing a portion of the virus responsible for COVID-19. If this sounds familiar, it's because vaccines from AstraZeneca (AZN 0.12%) and Johnson & Johnson (JNJ 0.55%) rely on similar technology. 

Coronavirus vaccines from AstraZeneca and Johnson & Johnson are the first viral-vector vaccines to be used beyond clinical trials, and so far, it's not going well. Before the FDA allows injections of TNX-1800 to reach millions of healthy people, it will be run through a much longer development process than investors are probably prepared for.

Sublingual cyclobenzaprine

Tonix Pharmaceuticals' most advanced new drug candidate, TNX-102, is essentially cyclobenzaprine in a new package. Cyclobenzaprine earned its first FDA approval in 1977, and it comes from a powerful class of drugs used extensively to treat depression and other chronic conditions. 

These days, the use of cyclobenzaprine is limited to short-term relief from muscle spasms. This is because physicians need to carefully monitor patients who take cyclobenzaprine for signs of abuse and unintentional overdosage that can be fatal.

While TNX-102 is in late-stage trials now, Tonix is facing a long uphill battle ahead. TNX-102 was designed to be held under the tongue to boost its efficacy, but that will also boost the FDA's concerns about its potential for abuse. 

Keep looking

Tonix Pharmaceuticals hasn't provided evidence that sublingual TNX-102 is an acceptable treatment option for chronic conditions that require long-term dosing. That makes its eventual approval for fibromyalgia extremely unlikely without successful results from a long-term safety study that addresses addiction. 

Tonix Pharmaceuticals has gotten its shareholders into a long slog uphill that you don't want any part of. More misguided enthusiasm could quickly drive it higher, but investors would do well to look for better biotech stocks to buy.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tonix Pharmaceuticals Holding Corp. Stock Quote
Tonix Pharmaceuticals Holding Corp.
TNXP
$1.57 (12.26%) $0.17
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.21 (0.55%) $0.91
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.72 (0.12%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.